Molteni SPA nominates the FarmaMondo Group as the exclusive partner for its pain and addiction portfolio in Egypt.

Molteni Farmaceutici and the FarmaMondo Group signed an exclusive marketing and distribution agreement for certain Molteni’s products of its pain and addiction management portfolio in Egypt.

Under the Agreement, FarmaMondo shall manage the approval and commercialization of Molteni’s products Oramorph® and Buprenorphine in Egypt.

This agreement once again reinforces the Group’s strategy and its constant endorsement by the industry stakeholders. We are proud to have gained such trust from Molteni to represent them in the biggest single market in the MENA region. The Group continues to expand its infrastructure in MENA to further support patient’s unmet needs across the region.


FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization

For more information about FarmaMondo please visit:


Molteni Farmaceutici SpA is a specialty leader in the opioid drug market, a responsible company that has always been committed to the research and implementation of therapeutic solutions for the treatment of pain and addictions to defend the patient’s quality of life and their right to adequate therapy.

For more information about Molteni Farmaceutici please visit: